We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+3.37%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$4.02B
AUM Growth
-$31.8M
Cap. Flow
+$159M
Cap. Flow %
3.95%
Top 10 Hldgs %
55.91%
Holding
627
New
130
Increased
130
Reduced
70
Closed
208

Sector Composition

Rank Sector Weight
1 Technology 28.76%
2 Energy 15.79%
3 Communication Services 7.77%
4 Consumer Staples 7.72%
5 Financials 7.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
COTY icon
176
PUT
Coty
COTY
$2.47B
$1.62M 0.04%
1,264,500
ALGS icon
177
Aligos Therapeutics
ALGS
$35.2M
$1.6M 0.04%
40,096
-27,000
-40% -$522K
ADT icon
178
ADT
ADT
$5.64B
$1.59M 0.04%
229,607
IFRX icon
179
InflaRx
IFRX
$267M
$1.55M 0.04%
625,589
-172,287
-22% -$331K
BAP icon
180
Credicorp
BAP
$30.9B
$1.52M 0.04%
8,311
KIDS icon
181
OrthoPediatrics
KIDS
$597M
$1.51M 0.04%
65,292
+13,270
+26% +$332K
ALGN icon
182
Align Technology
ALGN
$12.2B
$1.51M 0.04%
7,250
+1,800
+33% +$402K
FFIV icon
183
F5
FFIV
$23.4B
$1.51M 0.04%
+6,000
New +$1.43M
SWTX
184
DELISTED
SpringWorks Therapeutics
SWTX
$1.5M 0.04%
41,493
+12,980
+46% +$454K
POLE
185
Andretti Acquisition Corp II
POLE
$319M
$1.5M 0.04%
+150,000
New +$1.5M
NKTR icon
186
Nektar Therapeutics
NKTR
$2.5B
$1.47M 0.04%
105,394
+28,672
+37% +$506K
INCY icon
187
Incyte
INCY
$24.3B
$1.46M 0.04%
21,188
-2,683
-11% -$191K
KALV
188
DELISTED
KalVista Pharmaceuticals
KALV
$1.46M 0.04%
172,693
+37,141
+27% +$385K
ZS icon
189
Zscaler
ZS
$27.3B
$1.46M 0.04%
8,100
+4,100
+103% +$794K
CAPR icon
190
Capricor Therapeutics
CAPR
$251M
$1.45M 0.04%
104,798
+21,898
+26% +$384K
FNA
191
DELISTED
Paragon 28, Inc.
FNA
$1.43M 0.04%
138,854
-11,964
-8% -$96.6K
AGIO icon
192
Agios Pharmaceuticals
AGIO
$1.9B
$1.42M 0.04%
43,330
+22,243
+105% +$1.04M
RIGL icon
193
Rigel Pharmaceuticals
RIGL
$763M
$1.42M 0.04%
84,311
-32,604
-28% -$625K
CRNX icon
194
Crinetics Pharmaceuticals
CRNX
$8.91B
$1.42M 0.04%
27,687
+2,994
+12% +$168K
ORIC icon
195
Oric Pharmaceuticals
ORIC
$1.35B
$1.41M 0.04%
174,846
+31,526
+22% +$289K
YUMC icon
196
Yum China
YUMC
$16.3B
$1.39M 0.03%
+28,900
New +$1.37M
STNE icon
197
StoneCo
STNE
$2.63B
$1.38M 0.03%
173,478
+9,620
+6% +$97.5K
PLRX icon
198
Pliant Therapeutics
PLRX
$64.4M
$1.36M 0.03%
103,563
+18,678
+22% +$255K
RLAY icon
199
Relay Therapeutics
RLAY
$4.2B
$1.36M 0.03%
330,699
+218,651
+195% +$1.19M
IMCR icon
200
Immunocore
IMCR
$1.7B
$1.34M 0.03%
45,274
+10,162
+29% +$321K

Similar funds

UBS O'Connor's Q4 2024 Portfolio in Review

As of Q4 2024, UBS O'Connor held 627 positions worth $4.02B, down 0.79% from $4.05B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

UBS O'Connor deployed $159M of net new capital in Q4 2024, opening 130 new positions and adding to 130 existing holdings. Its largest new stake was Discover Financial Services: 1,166,698 shares worth $202M.

By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 20% a quarter earlier, followed by Energy and Communication Services.

On the sell side, the largest reduction was US Steel, an estimated $62.2M trimmed.

  • UBS O'Connor's largest Q4 2024 buy was Discover Financial Services: 1,166,698 shares worth $202M.
  • UBS O'Connor added most to Smartsheet Inc. in Q4 2024, an estimated $188M increase.
  • UBS O'Connor's biggest Q4 2024 reduction was US Steel, cutting an estimated $62.2M.
  • UBS O'Connor fully exited CATALENT, INC. in Q4 2024, selling an estimated $234M.
  • UBS O'Connor's ten largest holdings make up 56% of its $4.02B portfolio in Q4 2024.
  • UBS O'Connor opened 130 new positions and closed 208 in Q4 2024.
  • UBS O'Connor's portfolio value fell 0.79% quarter-over-quarter to $4.02B.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.